FIG. 2.

Percentage of subjects with a ≥4-fold increase in serum bactericidal antibody to vaccine-homologous or PorA-related and heterologous strains (assays done at GSK Biologicals). All subjects in the ATP cohort for immunogenicity (156 in the MenB 0-2-4m group, 151 in the MenB 0-1-6m group, and 150 in the control group) with results available for a specific assay were included in the analysis for that assay. See Table 1 for strain typing details. The response rate was statistically higher for BZ10 for the MenB 0-1-6m versus the MenB 0-2-4m group and statistically lower for all strains for the control versus the MenB 0-1-6m group (P < 0.05; two-sided Fisher's exact test).